Effects of As2O3 nanoparticles on cell growth and apoptosis of NB4 cells

Dong,Xiaoyan; Ma,Ning; Liu,Mengmeng; Liu,Ziling

doi:10.3892/etm.2015.2651

Effects of As2O3 nanoparticles on cell growth and apoptosis of NB4 cells

Authors:
- Xiaoyan Dong
- Ning Ma
- Mengmeng Liu
- Ziling Liu
View Affiliations

Affiliations: Department of Hematological Neoplasms, The First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: July 23, 2015 https://doi.org/10.3892/etm.2015.2651
Pages: 1271-1276
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the preparation of arsenic trioxide (As2O3) nanoparticles and examine the antitumor effects of these nanoparticles on NB4 cells. As2O3 nanoparticles were prepared using the sol‑gel method and characterized using transmission electron microscopy and energy dispersive spectroscopy. The results indicated that the As2O3 nanoparticles prepared in the present study were round or elliptical, well dispersed and had an ~40‑nm or <10‑nm diameter. The antitumor effects of As2O3 nanoparticles at various concentrations were analyzed by flow cytometry and the MTT assay, and were compared with those of traditional As2O3 solution. At the same concentration and incubation time (48 h), the survival rate of cells treated with As2O3 nanoparticles was significantly lower than that of cells treated with the As2O3 solution. The growth inhibition rate under both treatments was time‑ and dose‑dependent. In addition, at the same concentration and incubation time, the apoptosis rate of the cells treated with As2O3 nanoparticles was significantly higher than that of the cells treated with the As2O3 solution. Furthermore, As2O3 nanoparticles resulted in a greater reduction in the expression of the anti‑apoptotic protein B‑cell lymphoma 2 compared with the As2O3 solution. In conclusion, As2O3 nanoparticles, prepared using the sol‑gel method, were found to produce a stronger cytotoxic effect on tumor cells than that produced by the As2O3 solution, possibly by inhibiting Bcl-2 expression.

View Figures

View References

1	Hillestad LK: Acute promyelocytic leukemia. Acta Med Scand. 159:189–194. 1957. View Article : Google Scholar : PubMed/NCBI
2	Bernard J, Mathe G, Boulay J, Ceoard B and Chome J: Acute promyelocytic leukemia: A study made on 20 cases. Schweiz Med Wochenschr. 89:604–608. 1959.(In French). PubMed/NCBI
3	Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G and Gemon MF: Acute promyelocytic leukemia: Results of treatment by daunorubicin. Blood. 41:489–496. 1973.PubMed/NCBI
4	Ribeiro RC and Rego E: Management of APL in developing countries: Epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program. 162–168. 2006. View Article : Google Scholar : PubMed/NCBI
5	Zhang P, Wang SY, Hu LH, Shi FD, Qiu FG, Hong ZZ, Han XY, Yang H, Song YZ, Liu YP, et al: Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Zhong Hua Xue Ye Xue Za Zhi. 17:58–60. 1996.(In Chinese).
6	Wang ZY: Ham-Wasserman lecture: Treatment of acute leukemia by inducing differentiation and apoptosis. Hematology Am Soc Hematol Educ Program. 1–13. 2003. View Article : Google Scholar : PubMed/NCBI
7	Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A and Shah R: The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications Eur Heart. J. 21:1216–1231. 2000.
8	Unnikrishnan D, Dutcher JP, Garl S, Varshneya N, Lucariello R and Wiernik PH: Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol. 124:610–617. 2004. View Article : Google Scholar : PubMed/NCBI
9	Sinha R, Kim GJ, Nie S and Shin DM: Nanotechnology in cancer thearpeutics: Bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 5:1909–1917. 2006. View Article : Google Scholar : PubMed/NCBI
10	Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 5:161–171. 2005. View Article : Google Scholar : PubMed/NCBI
11	Sanna V, Pala N and Sechi M: Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 9:467–483. 2014.PubMed/NCBI
12	Song L: Preparation Method of MaterialMaterials Introduction. Zhou DF: Chemical Industry Press; Beijing: pp. 119–121. 2001
13	Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
14	Mazel S, Burtrum D and Petrie HT: Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med. 183:2219–2226. 1996. View Article : Google Scholar : PubMed/NCBI
15	Zhang X, Yang L and Qiao Z: An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid. Zhonghua Nei Ke Za Zhi. 38:113–115. 1999.(In Chinese). PubMed/NCBI
16	Liu L, Qin SK, Chen HY, Wang J, Chen H, Ma J and Liu W: An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes. Zhonghua Gan Zang Bing Za Zhi. 8:367–369. 2000.(In Chinese). PubMed/NCBI
17	Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, Yao YT, Chou WC, Chung CY, Wang CH, et al: Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukemia. Br J Haematol. 103:1092–1095. 1998. View Article : Google Scholar : PubMed/NCBI
18	Hu X, Ma L and Hu N: Ailing No. 1 in treating 62 cases of acute promyelocytic leukemia. Zhongguo Zhong Xi Yi Jie He Za Zhi. 19:473–476. 1999.(In Chinese). PubMed/NCBI
19	Wang MD, Shin DM, Simons JW and Nie S: Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther. 7:833–837. 2007. View Article : Google Scholar : PubMed/NCBI
20	Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A and Chandy M: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood. 107:2627–2632. 2006. View Article : Google Scholar : PubMed/NCBI
21	Huang YQ, Zhang YQ and Hua RQ: Preparation and properties of LLDPE/ Nano SiO₂ composites. Zhong Guo Su Liao. 17:252003.(In Chinese).
22	Zhao K, Chao YL and Yang Z: Development and property study of zirconia toughened nano-composite alumina ceramic powder for dental application. Zhonghua Kou Qiang Yi Xue Za Zhi. 38:384–386. 2003.(In Chinese). PubMed/NCBI
23	Wang ZY, Zhang DS, Lu XL, Yan SY, Jin LQ and Wan ML: Research of human liver cancer cell apoptosis induced by As₂O₃ nanoparticles. Yi Xue Yan Jiu Sheng Bao. 18:481–489. 2005.(In Chinese).
24	Wang Q, Wang ZY, Lin M, Zhang J, Zhao SS and Zhang DS: Application of As₂O₃ nanoparticles in treatment on human lung cancer in vivo and investigation of its anti-transfer mechanism. Na Mi Ji Shu He Jing Mi Gong Cheng. 6:99–102. 2008.(In Chinese).